Ambiotis

An inflammation specialization, a resolution expertise

Ambiotis was created in 2007 as a Young and Innovative Start-up and has been the first CRO worldwide working on the active resolution of inflammation. More than 50% of the activity is invested in R&D to provide always cutting edge research services.

Since its creation, Ambiotis has promoted the field of inflammation resolution, first discovered by Pr Charles Serhan at Harvard Medical School.

Ambiotis has dedicated its research to this field to build a thorough experience, now worldwide recognized.

With this knowledge, Ambiotis aims now to be the perfect partner for preclinical and clinical research in the field.

Driving values

• Advance the care of patients suffering from inflammatory disorders
• Promote the field of resolution pharmacology
• Help customers to solve their research questions
• Build a trustworthy relationship with our customers
• Allow a challenging and rewarding environment for our highly skilled researchers

Team

Management

Marc Dubourdeau, PhD, is the Chief Executive Officer (CEO) of Ambiotis. He obtained a PhD degree in Immunology from the University Paul Sabatier (Toulouse, France) and a Master’s Management degree from the Toulouse Business School (France).

Prior to Ambiotis’ creation, Marc Dubourdeau was working for the Institut Pasteur (Paris, France) where he was investigating the mechanisms of the inflammatory process in various infectious diseases.

Strategic advisory board

• Pr Charles N Serhan (Harvard Medical School)
• Dr Nathalie Vergnolle (Research Director INSERM)
• Pr Jean-Paul Latgé (Research Laboratory Director, Aspergillus Unit, Institut Pasteur),
• Pr Laurent Alric (Chief of Internal Medicine),

Ambiotis scientific team

Dynamic and highly skilled PhD, research engineers and higher technicians are working for Ambiotis. They are used to work in a competitive research environment and are also able to manage efficiently industrial projects.

Recruitment of people able to turn research challenges into solutions is therefore essential for Ambiotis.

Employment opportunities

Ambiotis can propose career opportunities for motivated people with different educational backgrounds, skills, and interests. If you are interested in:

• working in a high-tech environment, where state-of- the-art science is practiced every day,
• joining a young, dynamic, and growing organization,
• continuously developing your skills, and
• meeting new challenges,

They trust us

« Our collaboration with Ambiotis started in 2018 and we have since collaborated on multiple occasions. The team is highly dynamic and efficient, and always does its best to answer our scientific problematic with high quality work. »

Laurent Garçon

Co-founder Nuvamid SA Lausanne – Switzerland

.

"We collaborated with Ambiotis to develop a new efficacy model surrounding inflammatory resolution, a model that was key in the development of a powerful and innovative active ingredient."

Nicolas Bechetoille, Research Manager Skin Biology

Gattefossé

"We are working with Ambiotis for a couple of years for specific cellular assays and appreciate very much their technical expertise and the resulting data quality. They are also interested and very open to discuss the science and optimize together the experiment design to make sure our goals are achieved in a clear and efficient manner. They are an uncomplicated preclinical partner which complements very well our own team."

Senior Research Scientist, Swiss biotech

In our collaboration with Ambiotis, we evaluated the effect of our product HE-100 on inflammation resolution. Ambiotis’s expertise in this field led to successful completion of our Research Program. The data were presented at the New York Academy of Sciences (NYAS) in June 2018 in a symposium titled: “Resolution of Inflammation, Infection and Tissue Regeneration”.

"As a global leader in plant-based ingredients for food, nutrition and health markets, we are committed to working in close collaboration with international experts. We really enjoyed working with Ambiotis to assess the anti-inflammatory properties of our products. We particularly appreciated the quality of the results and the respect of the deadlines."

Dr Damien Truffin

Toxicology expert

Most of all, we appreciated the quality of our scientific discussion on the study design, the customer support, and the follow-up and thoroughness of the results shared."

Kader THIAM

Senior VP Discovery & Preclinical Models at genOway

You are a customer or a partner and want to give your feedback about Ambiotis work ? Do it by contact form

They support us